ReGenTree begins ARISE-3 trial of RGN-259 eye drops for dry eye syndrome
ReGenTree has initiated a phase 3 clinical trial, called ARISE-3, to evaluate the safety and efficacy of 0.1% RGN-259 eye
Continue readingCoverage of Global Pharma Industry News
ReGenTree has initiated a phase 3 clinical trial, called ARISE-3, to evaluate the safety and efficacy of 0.1% RGN-259 eye
Continue readingBiogen acquisition of Nightstar Therapeutics : US biotech company Biogen has signed a deal of $800 million to acquire Nightstar
Continue readingBridgeBio Pharma, a clinical-stage biopharma company focused on the development of drugs for genetic diseases, raised $299.2 million in a
Continue readingThe US Food and Drug Administration (FDA) has accepted to review the New Drug Application (NDA) for KPI-121 0.25%, an
Continue readingClinical trial news : Kodiak Sciences has completed enrollment of patients for a phase 1 safety and tolerability study to
Continue reading